Nitric Oxide - Therapeutics, Markets and Companies

Questions: Discounts, Updates etc.

Pages: 266

Price: US$ 2,800 (electronic).

Publication Date: 2009-01-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.

Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signaling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches.

Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhaltion for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.

Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described. The text is supplemented with 25 tables and 20 figures.

Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2006 and is projected to 2010 and 2015 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.

The number of companies that have a product or products involving NO and free radicals isquite large and difficult to determine precisely as this is not the main focus of these companies. The report includes profiles of 36 companies involved in this area of which 9 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important collaborations in this area are tabulated.

There are over 80,000 publications relevant to NO. Selected 400 references are included in bibliography. It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in humantherapeutics.

Table of Contents

Download Table of Contents as a PDF

Other users found this report page using the following search terms: Nitric Oxide nos inos nitric oxide drugs companies drug company therapeutics nitrix markets pharmaceutical

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.